Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Shares Outstanding (2016 - 2025)

Guided Therapeutics' Shares Outstanding history spans 11 years, with the latest figure at $83599.0 for Q3 2025.

  • For Q3 2025, Shares Outstanding rose 4179850.0% year-over-year to $83599.0; the TTM value through Sep 2025 reached $83599.0, up 4179850.0%, while the annual FY2024 figure was $1.0, 100.0% down from the prior year.
  • Shares Outstanding for Q3 2025 was $1.0 at Guided Therapeutics, down from $79.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $79.0 million in Q2 2025 and bottomed at $1.0 in Q4 2023.
  • The 5-year median for Shares Outstanding is $1000.0 (2021), against an average of $7.4 million.
  • The largest annual shift saw Shares Outstanding soared 4859471.5% in 2022 before it crashed 100.0% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $1000.0 in 2021, then skyrocketed by 4859471.5% to $48.6 million in 2022, then plummeted by 100.0% to $2.0 in 2023, then crashed by 50.0% to $1.0 in 2024, then soared by 8359800.0% to $83599.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Shares Outstanding are $83599.0 (Q3 2025), $1.0 (Q2 2025), and $1000.0 (Q1 2025).